As Merck and Pfizer predict incoming billions from their COVID drugs, Roche culls pandemic ties with Atea CDC: Record-breaking more than 100K died of overdoses over one-year period FDA grants first approval for a VR system to treat chronic lower back pain Pfizer's D'Amelio retires, spurring 'external' CFO search and prompting company to name new supply chief Report: Most physicians worry telehealth made them miss signs of drug abuse during the pandemic Biogen’s Aduhelm, already battling US skepticism, faces likely European rejection Eloxx ends long wait for phase 2 cystic fibrosis data. Market shrugs Unions hope tentative deal with Kaiser Permanente sends a message about two-tier wage systems Cala Health scores $77M to expand its tremor-fighting wearable to new conditions New Cures 2.0 bill extends key telehealth flexibilities, hastens CMS approval of medical devices Fine-tuning targeted therapy for multiple myeloma with 'multi-omics' data Rapper Common encourages lung cancer screenings, clinical trials for Black community in Bristol Myers-backed PSA COVID test maker Sense Biodetection pads venture round with another $15M About 77% of clinical research execs expect to run decentralized trials in next 12 months: survey Featured Story | By Ben Adams Swiss major Roche is cutting its losses and casting aside its COVID drug collab with biotech Atea Pharmaceuticals. read more |
| |
|---|
|
|
| Spinal Muscular Atrophy: Overview & Outlook SMA is a rare and devastating disease. This 2-part series provides an overview of SMA and current therapies. It also provides an outlook on potential advancements that could affect the therapeutic and commercial landscapes. Download now. |
Top Stories By Robert King A record-breaking 100,306 people died from a drug overdose from April 2020 through April 2021 due in part to the COVID-19 pandemic as the federal government offers new strategies to curb the rising number of deaths, new CDC data shows. read more By Andrea Park In a first for the FDA, the agency approved a virtual reality device to treat lower back pain, offering up an opioid-free alternative to many current pain management regimens. read more By Fraiser Kansteiner Frank D’Amelio, Pfizer’s current chief financial officer and executive vice president of global supply, is retiring, the company said Wednesday. The company has started the search for a replacement and named Mike McDermott its new chief of global supply. read more By Rebecca Torrence A new report by Quest Diagnostics shows providers worry that virtual visits allow signs of drug abuse to slip by unnoticed. The majority surveyed said they fear they missed signs of drug abuse in their patients while using telehealth last year. read more By Angus Liu European regulators don’t plan to go down the same controversial path as their U.S. counterparts did in approving Biogen’s Eisai-partnered Alzheimer’s disease therapy, Aduhelm. And for Biogen, as one analyst sees it, 40% of potential revenue on the drug is going down the drain. read more By Nick Paul Taylor The long wait for phase 2 data on Eloxx Pharmaceuticals’ cystic fibrosis prospect is over—and yet the picture remains unclear. Eloxx brushed over the failure to improve lung function in the small, short clinical trial, choosing instead to focus on a narrow win against a biomarker endpoint. read more By Robert King Unions believe Kaiser Permanente's decision to back off a two-tier wage system in a tentative deal that averted a major strike could have a ripple effect across the hospital industry. read more By Conor Hale After showing its wrist-worn bioelectronic device could help people reduce hand tremors, Cala Health has raised $77 million to help expand its technology to new uses in Parkinson’s disease and other conditions. read more By Robert King New legislation would make permanent key telehealth flexibilities and let Medicare cover newly approved medical devices faster. read more By Angus Liu Mount Sinai scientists analyzed biological datasets from multiple myeloma patients and generated a computational model that allowed them to identify new subtypes of the disease. Armed with the results, they identified potential targeted treatments for patients who fall into those subtypes. read more By Natalie Missakian Actor and rapper Common is teaming up with Bristol Myers Squibb and Stand Up to Cancer to give people the facts about the disproportionate rates of lung cancer in the Black community. In a new PSA, he calls on viewers to help change those statistics by learning more about screening and clinical trials. read more By Andrea Park The tacked-on funds from Koch Disruptive Technologies bring Sense Biodetection’s series B haul to $65 million. read more By Kyle LaHucik Decentralized clinical trials picked up steam during the COVID-19 pandemic, and they might end up outpacing the growth of traditional site-based studies within the next 12 months. That's the result of a survey from virtual trials provider Science 37, which asked 127 senior clinical research executives about the hybrid studies landscape. read more | 